Global Liquid Biopsy Market: Focus on Market Segmentation by Product Type, by Indication Type, by Technology, by Biomarker, by Clinical Applications, by Sample Type, by Usage, By Workflow, Geographical and Competitive Landscape - Analysis and Forecast, 2020-2030
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
Market Report Coverage - Global Liquid Biopsy
Market Segmentation
GUARDANT HEALTH, Biocept, Bio-Rad Laboratories, Cynvenio Biosystems, Chronix Biomedical,Illumina ,and Neogenomics Laboratories, among others.
Key Questions Answered in this Report:
Liquid biopsy is anon-invasive clinical alternative to surgical tissue biopsies. Performing liquid biopsies enables physicians to discover a wider range of information about tumors through the assessment of blood or other fluid-basedsamples from a perspective cancer patient.
Traditionally, the liquid biopsy services were mainly focused on oncology settings, such as treatment decisions, recurrence monitoring, and screening. However, with the advent of new players in the liquid biopsy market, transplant rejection assessment services and infectious disease services based on liquid biopsies areset to become eminent parts of current practices. Several players, such as GUARDANT HEALTH, CareDX, and Chronix Biomedical,currently offer these services in the market. The entry of new players in the market, coupled up with the increased innovation pertaining to cost mitigation and resource output maximization,has been transforming the market currently.
The existing market of liquid biopsy is favored by multiple factors, includingrising prevalence of cancers, increasing adoption of inorganic growth strategies in the market, and increased NCI funding.
Within the research report, the market is segmented on the basis of technology offered by key players (NGS, PCR, FISH, and other technologies), workflow (sample preparation, library preparation, sequencing, and data analysis), usage (RUO and diagnostic), sample (blood and non-blood samples), circulating biomarker (circulating tumor cells, cell-free DNA, circulating RNA, exosomes and extracellular vesicles, and others), product (test/services, kits and consumables, and instruments), oncology indication type (lung cancer, breast cancer, prostate cancer, colorectal cancer, melanoma, and other cancers), clinical application (treatment monitoring, prognosis and recurrence monitoring, treatment selection, diagnosis, and screening), and region (North America, Europe, Latin America and Middle East, and Asia-Pacific). This segmentation highlights value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, future opportunities, among others, to detail the scope and provide a 360° coverage of the domain.
Competitive Landscape
Major players, including GUARDANT HEALTH, Biocept, Bio-Rad Laboratories, and Cynvenio Biosystems, among others, led the number of synergistic developments (partnerships and alliances) witnessed inthe market. On the basis of region, North America is expected to retain a leading position throughout the forecast period 2020-2030, followed byEurope. The high growth is attributed to the presence of leading industry players in North America, coupled up with therising prevalenceof cancer.
Market Report Coverage - Global Liquid Biopsy
Market Segmentation
- By Technology: Next-Generation Sequencing, Polymerase Chain Reaction and Other Technologies
- By Workflow: Sample Collection and Preparation, Library Preparation, Sequencing, and Data Analysis and Management
- By Usage: Research, Clinical
- By Sample:Blood, Urine, Saliva, and Cerebrospinal Fluid
- By Circulating Biomarker: Circulating Tumor Cells,Cell-free DNA,Circulating Cell-Free RNA,Exosomes and Extracellular Vesicles,and Others
- By Products: Tests/Services, Kits and Consumables, and Instruments
- By Indication: Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Other Cancers, and Non-Oncology Disorders
- By Clinical Application:Treatment Monitoring,Prognosis and Recurrence Monitoring, Treatment Selection, and Diagnosis and Screening
- By Region: North America, Europe, Asia-Pacific,Latin America and Middle East, and Rest-of-the-World
- North America – U.S., Canada
- Europe – Germany, France, U.K., Italy, Spain, Rest-of-Europe
- Asia-Pacific – China, Japan, India, Australia, South Korea, Singapore, Rest-of-Asia-Pacific
- Latin America and Middle East– Brazil, Mexico, Saudi Arabia, Rest-of-Latin America and Middle East
- Rest-of-the-World
- Rising Prevalence of Cancers
- Increasing Adoption of Inorganic Growth Strategies in the Market
- Increased NCI funding
- False Negatives and Positives
- Uncertain Reimbursement and Regulatory Scenario
- Existing Diagnostic Confidence on Standard Tumor Biopsies
- Expected Implementation of Patient Protection and Affordable Care Act
- Potential Cost Savings
- Existing Applicability in Non-Availability of Tissue Sections for Traditional Biopsy Approaches
- Entry of Major Players in the Organ Transplantation Liquid Biopsy Segment
GUARDANT HEALTH, Biocept, Bio-Rad Laboratories, Cynvenio Biosystems, Chronix Biomedical,Illumina ,and Neogenomics Laboratories, among others.
Key Questions Answered in this Report:
- What are liquid biopsies? How different settings for liquid biopsieshave evolvedover the centuries?
- What are the major market drivers, challenges, and opportunities in the global liquid biopsymarket?
- What was the global liquid biopsy market size in terms of revenue in 2019? How is the market expected to evolve in during the forecast period, 2020-2030? What is the expected market size in 2030?
- How is each segment of the global liquid biopsy market expected to grow during the forecast period between 2020 to 2030,and what revenue is expected to be generated by each of the segments by the end of 2030?
- What are the developmental strategies implemented by the key players to sustain in the competitive market?
- What is the growth potential of the global liquid biopsyin different countries?
- Which service segments among oncology and non-oncology are offered by the key players such asGUARDANT HEALTH, INIVATA, and FOUNDATION MEDICINE?
- Which liquid biopsy segment led the market in 2019?Which segment is expected to dominate the market by2030, and why?
- Which application type led the market in 2019?Which segment is expected to dominate the market by2030, and why?
- Which region dominated the global liquid biopsy market in 2019, and what are the expected trends from each region overthe forecast period 2020-2030?
Liquid biopsy is anon-invasive clinical alternative to surgical tissue biopsies. Performing liquid biopsies enables physicians to discover a wider range of information about tumors through the assessment of blood or other fluid-basedsamples from a perspective cancer patient.
Traditionally, the liquid biopsy services were mainly focused on oncology settings, such as treatment decisions, recurrence monitoring, and screening. However, with the advent of new players in the liquid biopsy market, transplant rejection assessment services and infectious disease services based on liquid biopsies areset to become eminent parts of current practices. Several players, such as GUARDANT HEALTH, CareDX, and Chronix Biomedical,currently offer these services in the market. The entry of new players in the market, coupled up with the increased innovation pertaining to cost mitigation and resource output maximization,has been transforming the market currently.
The existing market of liquid biopsy is favored by multiple factors, includingrising prevalence of cancers, increasing adoption of inorganic growth strategies in the market, and increased NCI funding.
Within the research report, the market is segmented on the basis of technology offered by key players (NGS, PCR, FISH, and other technologies), workflow (sample preparation, library preparation, sequencing, and data analysis), usage (RUO and diagnostic), sample (blood and non-blood samples), circulating biomarker (circulating tumor cells, cell-free DNA, circulating RNA, exosomes and extracellular vesicles, and others), product (test/services, kits and consumables, and instruments), oncology indication type (lung cancer, breast cancer, prostate cancer, colorectal cancer, melanoma, and other cancers), clinical application (treatment monitoring, prognosis and recurrence monitoring, treatment selection, diagnosis, and screening), and region (North America, Europe, Latin America and Middle East, and Asia-Pacific). This segmentation highlights value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, future opportunities, among others, to detail the scope and provide a 360° coverage of the domain.
Competitive Landscape
Major players, including GUARDANT HEALTH, Biocept, Bio-Rad Laboratories, and Cynvenio Biosystems, among others, led the number of synergistic developments (partnerships and alliances) witnessed inthe market. On the basis of region, North America is expected to retain a leading position throughout the forecast period 2020-2030, followed byEurope. The high growth is attributed to the presence of leading industry players in North America, coupled up with therising prevalenceof cancer.
EXECUTIVE SUMMARY
1 PRODUCT DEFINITION
1.1 Inclusion and Exclusion
2 MARKET SCOPE
2.1 Scope of Work
2.2 Key Questions Answered in the Report
3 RESEARCH METHODOLOGY
3.1 Global Liquid Biopsy Market: Research Methodology
3.2 Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.4.1 Assumptions and Limitations
3.4.2 Data and Prediction Modeling
3.5 Criteria for Company Profiling
4 MARKET OVERVIEW
4.1 Market Size and Future Growth Potential
4.2 Historical Trends
4.3 Comparative Analysis of Tissue Biopsy and Liquid Biopsy
4.4 Comparative Analysis of Liquid Biopsy Technologies
5 INDUSTRY INSIGHTS
5.1 Approval Scenario
5.1.1 Approved Liquid Biopsy by Major Players
5.1.2 Launched Liquid Biopsies by Major Players
5.2 Regulatory Framework
5.2.1 Regulatory Framework in the U.S
5.2.1.1 Guidelines Recommendation
5.2.1.2 Regulatory path for liquid biopsy diagnostic approvals
5.2.2 Regulatory Framework in the European Union
5.2.3 Regulation in Other Countries
5.3 Reimbursement Scenario
5.3.1 Case Study for Liquid Biopsy Reimbursement Analysis
5.4 Patent Analysis
5.4.1 Key Players Patent Portfolio
5.4.2 Patent Filing Analysis
5.4.3 Key Players Patent Expiration Analysis
5.5 Financing Scenario
5.5.1 Key Players Stratification (as Per Raised Financing Value)
5.5.2 Key Players Financing Analysis (FY2017-2019)
5.5.3 Investment Heat Map
5.5.4 Investors Heat Map
5.6 Supply Chain Analysis
5.7 Product Mapping Analysis
5.7.1 By Technology
5.7.2 By Sample Type
5.7.3 By Biomarker
5.7.4 By Application
5.8 Physicians Perception
5.9 Investors Perception
5.1 Liquid Biopsy Government Initiatives
5.11 Implication of COVID-19 Pandemic on Liquid Biopsy Market
6 MARKET DYNAMICS
6.1 Market Drivers
6.1.1 Rising Cancer Prevalence
6.1.2 Increasing Adoption of Inorganic Growth Strategies in the Market
6.1.3 Increase in Research Funding from National Cancer Institute
6.2 Market Restraints
6.2.1 False Negatives and Positives
6.2.2 Uncertain Reimbursement and Regulatory Policies
6.2.3 Expected Implementation of Patient Protection and Affordable Care Act in the U.S
6.2.4 Existing Diagnostic Confidence on Traditional Tissue-Based Diagnosis Practices
6.3 Market Opportunities
6.3.1 Potential Cost Savings
6.3.2 Existing Applicability in Non-Availability of Tissue Sections for Traditional Biopsy Approaches
7 COMPETITIVE INSIGHTS
7.1 Key Strategies and Developments
7.1.1 Synergistic Activities
7.1.2 Regulatory Accreditations
7.1.3 Product and Service Launches
7.1.4 Acquisitions and Mergers
7.1.5 Approvals
7.2 Market Share Analysis, 2019
7.3 Growth Share Analysis
7.3.1 Growth Share Analysis (by Prominent Companies)
7.3.2 Growth Share Analysis (by Technology)
7.3.3 Growth Share Analysis (by Indication)
7.3.4 Growth Share Analysis (by Biomarker Type)
7.3.5 Growth Share Analysis (by Clinical Application)
8 GLOBAL LIQUID BIOPSY MARKET (BY PRODUCT)
8.1 Tests/Services
8.2 Kits and Consumables
8.3 Instruments
9 GLOBAL LIQUID BIOPSY MARKET (BY TECHNOLOGY)
9.1 Overview
9.2 Next-Generation Sequencing
9.3 Polymerase Chain Reaction
9.3.1 Digital PCR
9.3.2 Multiplex PCR
9.3.3 Real-Time PCR
9.3.4 Others
9.3.5 Fluorescence In-Situ Hybridization
9.4 Other Technologies
10 GLOBAL LIQUID BIOPSY MARKET (BY WORKFLOW)
10.1 Sample Preparation
10.2 Library Preparation
10.3 Sequencing
10.4 Data Analysis and Management
11 GLOBAL LIQUID BIOPSY MARKET (BY USAGE)
11.1 Overview
11.2 Clinical
11.3 Research
12 GLOBAL LIQUID BIOPSY MARKER (BY TYPE OF SAMPLE)
12.1 Overview
12.2 Blood
12.3 Non-Blood Samples
12.3.1 Urine
12.3.2 Saliva
12.3.3 Cerebrospinal Fluid Samples
13 GLOBAL LIQUID BIOPSY MARKET (BY CIRCULATING BIOMARKER)
13.1 Circulating Tumor Cells (CTCs)
13.2 Cell-Free DNA (cfDNA)
13.3 Circulating Cell-Free RNAs
13.4 Exosomes and Extracellular Vesicles and Others
13.5 Other Biomarkers
14 GLOBAL LIQUID BIOPSY MARKET (BY INDICATION)
14.1 Lung Cancer
14.2 Breast Cancer
14.3 Prostate Cancer
14.4 Colorectal Cancer
14.5 Melanoma
14.6 Other Types of Cancer
14.7 Non-Oncology Disorders
15 GLOBAL LIQUID BIOPSY MARKET (BY CLINICAL APPLICATION)
15.1 Treatment Monitoring
15.2 Prognosis and Recurrence Monitoring
15.3 Treatment Selection
15.4 Diagnosis and Screening
16 GLOBAL LIQUID BIOPSY MARKET (BY REGION)
16.1 North America
16.1.1 U.S.
16.1.1.1 U.S. Liquid Biopsy Market (by Oncology Indication)
16.1.2 Canada
16.1.2.1 Canada Liquid Biopsy Market (by Oncology Indication)
16.2 Europe
16.2.1 Germany
16.2.1.1 Germany Liquid Biopsy Market (by Oncology Indication)
16.2.2 France
16.2.2.1 France Liquid Biopsy Market (by Oncology Indication)
16.2.3 U.K.
16.2.3.1 U.K. Liquid Biopsy Market (by Oncology Indication)
16.2.4 Italy
16.2.4.1 Italy Liquid Biopsy Market (by Oncology Indication)
16.2.5 Spain
16.2.5.1 Spain Liquid Biopsy Market (by Oncology Indication)
16.2.6 Rest-of-Europe
16.3 Asia-Pacific
16.3.1 China
16.3.1.1 China Liquid Biopsy Market (by Oncology Indication)
16.3.2 Japan
16.3.2.1 Japan Liquid Biopsy Market (by Oncology Indication)
16.4 India
16.4.1 India Liquid Biopsy Market (by Oncology Indication)
16.4.2 Australia
16.4.2.1 Australia Liquid Biopsy Market (by Oncology Indication)
16.4.3 South Korea
16.4.3.1 South Korea Liquid Biopsy Market (by Oncology Indication)
16.4.4 Singapore
16.4.4.1 Singapore Liquid Biopsy Market (by Oncology Indication)
16.5 Rest-of-Asia-Pacific
16.6 Latin America and Middle East
16.6.1 Brazil
16.6.1.1 Brazil Liquid Biopsy Market (by Oncology Indication)
16.6.2 Mexico
16.6.2.1 Mexico Liquid Biopsy Market (by Oncology Indication)
16.6.3 Saudi Arabia
16.6.3.1 Saudi Arabia Liquid Biopsy Market (by Oncology Indication)
16.6.4 Rest-of-Latin America and Middle East
16.7 Rest-of-the-World
17 COMPANY PROFILES
17.1 Overview
17.2 Abcodia Ltd.
17.2.1 Company Overview
17.2.2 Role of Abcodia Ltd. in the Liquid Biopsy Market
17.2.3 SWOT Analysis
17.3 Biocept, Inc.
17.3.1 Company Overview
17.3.2 Role of Biocept, Inc. in Liquid Biopsy Market
17.3.3 Financials
17.3.4 Key Insights About Financial Health of the Company
17.3.5 SWOT Analysis
17.4 Bio-Rad Laboratories, Inc.
17.4.1 Company Overview
17.4.2 Role of Bio-Rad Laboratories, Inc. in Liquid Biopsy Market
17.4.3 Financials
17.4.4 Key Insights About Financial Health of the Company
17.4.5 SWOT Analysis
17.5 Cynvenio Biosystems, Inc.
17.5.1 Company Overview
17.5.2 Role of Cynvenio Biosystems, Inc. in the Liquid Biopsy Market
17.5.3 SWOT Analysis
17.6 Chronix Biomedical
17.6.1 Company Overview
17.6.2 Role of Chronix Biomedical in the Liquid Biopsy Market
17.6.3 SWOT Analysis
17.7 Epic Sciences, Inc.
17.7.1 Company Overview
17.7.2 Role of Epic Sciences, Inc. in the Liquid Biopsy in the Market
17.7.3 SWOT Analysis
17.8 F. Hoffmann-La Roche AG
17.8.1 Company Overview
17.8.2 Role of F. Hoffmann-La Roche AG in the Liquid Biopsy Market
17.8.3 Financials
17.8.4 Key Insights About Financial Health of the Company
17.8.5 SWOT Analysis
17.9 GUARDANT HEALTH, INC
17.9.1 Company Overview
17.9.2 Role of GUARDANT HEALTH, Inc. in Liquid Biopsy Market
17.9.3 Financials
17.9.4 Key Insights About Financial Health of the Company
17.9.5 Early Detection Strategy
17.9.5.1 Targeting Asymptomatic Population
17.9.5.2 Pilot Data on LUNAR-2 Lung Sensitivity by Stage
17.9.6 SWOT Analysis
17.10 Illumina, Inc.
17.10.1 Company Overview
17.10.2 Role of Illumina, Inc. in the Liquid Biopsy Market
17.10.3 Financials
17.10.4 Key Insights About Financial Health of the Company
17.10.5 SWOT Analysis
17.11 Menarini Silicon Biosystems, Inc.
17.11.1 Company Overview
17.11.2 Role of Menarini Silicon Biosystems in the Liquid Biopsy Market
17.11.3 SWOT Analysis
17.12 NeoGenomics Laboratories, Inc.
17.12.1 Company Overview
17.12.2 Role of NeoGenomics Laboratories, Inc. in the Liquid Biopsy Market
17.12.3 Financials
17.12.4 Key Insights About Financial Health of the Company
17.12.5 SWOT Analysis
17.13 Personal Genome Diagnostics, Inc.
17.13.1 Company Overview
17.13.2 Role of Personal Genome Diagnostics in the Liquid Biopsy Market
17.13.3 SWOT Analysis
17.14 Qiagen N.V.
17.14.1 Company Overview
17.14.2 Role of Qiagen N.V. in the Liquid Biopsy Market
17.14.3 Financials
17.14.4 Key Insights about Financial Health of the Company
17.14.5 SWOT Analysis
17.15 Resolution Bioscience, Inc.
17.15.1 Company Overview
17.15.2 Role of Resolution Biosciences, Inc. in the Liquid Biopsy Market
17.15.3 SWOT Analysis
17.16 Thermo Fisher Scientific
17.16.1 Company Overview
17.16.2 Role of Thermo Fisher Scientific in the Liquid Biopsy Market
17.16.3 Financials
17.16.4 Key Insights About Financial Health of the Company
17.16.5 SWOT Analysis
17.17 Exact Sciences Corporation
17.17.1 Company Overview
17.17.2 Role of Exact Sciences in the Global Liquid Biopsy Market
17.17.3 Financials
17.17.4 Key Insights About Financial Health of the Company
17.17.5 Early Detection Strategy
17.17.6 SWOT Analysis
17.18 Natera
17.18.1 Company Overview
17.18.2 Role of Natera Inc. in the Global Liquid Biopsy Market
17.18.3 Financials
17.18.4 Key Insights About Financial Health of the Company
17.18.5 SWOT Analysis
17.19 GRAIL
17.19.1 Company Overview
17.19.2 Role of GRAIL in the Liquid Biopsy Market
17.19.3 SWOT Analysis
17.20 Freenome
17.20.1 Company Overview
17.20.2 Role of Freenome in the Liquid Biopsy Market
17.20.3 SWOT Analysis
17.21 Thrive Earlier Detection
17.21.1 Company Overview
17.21.2 Role of Thrive Earlier Detection in the Liquid Biopsy Market
17.21.3 SWOT Analysis
1 PRODUCT DEFINITION
1.1 Inclusion and Exclusion
2 MARKET SCOPE
2.1 Scope of Work
2.2 Key Questions Answered in the Report
3 RESEARCH METHODOLOGY
3.1 Global Liquid Biopsy Market: Research Methodology
3.2 Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.4.1 Assumptions and Limitations
3.4.2 Data and Prediction Modeling
3.5 Criteria for Company Profiling
4 MARKET OVERVIEW
4.1 Market Size and Future Growth Potential
4.2 Historical Trends
4.3 Comparative Analysis of Tissue Biopsy and Liquid Biopsy
4.4 Comparative Analysis of Liquid Biopsy Technologies
5 INDUSTRY INSIGHTS
5.1 Approval Scenario
5.1.1 Approved Liquid Biopsy by Major Players
5.1.2 Launched Liquid Biopsies by Major Players
5.2 Regulatory Framework
5.2.1 Regulatory Framework in the U.S
5.2.1.1 Guidelines Recommendation
5.2.1.2 Regulatory path for liquid biopsy diagnostic approvals
5.2.2 Regulatory Framework in the European Union
5.2.3 Regulation in Other Countries
5.3 Reimbursement Scenario
5.3.1 Case Study for Liquid Biopsy Reimbursement Analysis
5.4 Patent Analysis
5.4.1 Key Players Patent Portfolio
5.4.2 Patent Filing Analysis
5.4.3 Key Players Patent Expiration Analysis
5.5 Financing Scenario
5.5.1 Key Players Stratification (as Per Raised Financing Value)
5.5.2 Key Players Financing Analysis (FY2017-2019)
5.5.3 Investment Heat Map
5.5.4 Investors Heat Map
5.6 Supply Chain Analysis
5.7 Product Mapping Analysis
5.7.1 By Technology
5.7.2 By Sample Type
5.7.3 By Biomarker
5.7.4 By Application
5.8 Physicians Perception
5.9 Investors Perception
5.1 Liquid Biopsy Government Initiatives
5.11 Implication of COVID-19 Pandemic on Liquid Biopsy Market
6 MARKET DYNAMICS
6.1 Market Drivers
6.1.1 Rising Cancer Prevalence
6.1.2 Increasing Adoption of Inorganic Growth Strategies in the Market
6.1.3 Increase in Research Funding from National Cancer Institute
6.2 Market Restraints
6.2.1 False Negatives and Positives
6.2.2 Uncertain Reimbursement and Regulatory Policies
6.2.3 Expected Implementation of Patient Protection and Affordable Care Act in the U.S
6.2.4 Existing Diagnostic Confidence on Traditional Tissue-Based Diagnosis Practices
6.3 Market Opportunities
6.3.1 Potential Cost Savings
6.3.2 Existing Applicability in Non-Availability of Tissue Sections for Traditional Biopsy Approaches
7 COMPETITIVE INSIGHTS
7.1 Key Strategies and Developments
7.1.1 Synergistic Activities
7.1.2 Regulatory Accreditations
7.1.3 Product and Service Launches
7.1.4 Acquisitions and Mergers
7.1.5 Approvals
7.2 Market Share Analysis, 2019
7.3 Growth Share Analysis
7.3.1 Growth Share Analysis (by Prominent Companies)
7.3.2 Growth Share Analysis (by Technology)
7.3.3 Growth Share Analysis (by Indication)
7.3.4 Growth Share Analysis (by Biomarker Type)
7.3.5 Growth Share Analysis (by Clinical Application)
8 GLOBAL LIQUID BIOPSY MARKET (BY PRODUCT)
8.1 Tests/Services
8.2 Kits and Consumables
8.3 Instruments
9 GLOBAL LIQUID BIOPSY MARKET (BY TECHNOLOGY)
9.1 Overview
9.2 Next-Generation Sequencing
9.3 Polymerase Chain Reaction
9.3.1 Digital PCR
9.3.2 Multiplex PCR
9.3.3 Real-Time PCR
9.3.4 Others
9.3.5 Fluorescence In-Situ Hybridization
9.4 Other Technologies
10 GLOBAL LIQUID BIOPSY MARKET (BY WORKFLOW)
10.1 Sample Preparation
10.2 Library Preparation
10.3 Sequencing
10.4 Data Analysis and Management
11 GLOBAL LIQUID BIOPSY MARKET (BY USAGE)
11.1 Overview
11.2 Clinical
11.3 Research
12 GLOBAL LIQUID BIOPSY MARKER (BY TYPE OF SAMPLE)
12.1 Overview
12.2 Blood
12.3 Non-Blood Samples
12.3.1 Urine
12.3.2 Saliva
12.3.3 Cerebrospinal Fluid Samples
13 GLOBAL LIQUID BIOPSY MARKET (BY CIRCULATING BIOMARKER)
13.1 Circulating Tumor Cells (CTCs)
13.2 Cell-Free DNA (cfDNA)
13.3 Circulating Cell-Free RNAs
13.4 Exosomes and Extracellular Vesicles and Others
13.5 Other Biomarkers
14 GLOBAL LIQUID BIOPSY MARKET (BY INDICATION)
14.1 Lung Cancer
14.2 Breast Cancer
14.3 Prostate Cancer
14.4 Colorectal Cancer
14.5 Melanoma
14.6 Other Types of Cancer
14.7 Non-Oncology Disorders
15 GLOBAL LIQUID BIOPSY MARKET (BY CLINICAL APPLICATION)
15.1 Treatment Monitoring
15.2 Prognosis and Recurrence Monitoring
15.3 Treatment Selection
15.4 Diagnosis and Screening
16 GLOBAL LIQUID BIOPSY MARKET (BY REGION)
16.1 North America
16.1.1 U.S.
16.1.1.1 U.S. Liquid Biopsy Market (by Oncology Indication)
16.1.2 Canada
16.1.2.1 Canada Liquid Biopsy Market (by Oncology Indication)
16.2 Europe
16.2.1 Germany
16.2.1.1 Germany Liquid Biopsy Market (by Oncology Indication)
16.2.2 France
16.2.2.1 France Liquid Biopsy Market (by Oncology Indication)
16.2.3 U.K.
16.2.3.1 U.K. Liquid Biopsy Market (by Oncology Indication)
16.2.4 Italy
16.2.4.1 Italy Liquid Biopsy Market (by Oncology Indication)
16.2.5 Spain
16.2.5.1 Spain Liquid Biopsy Market (by Oncology Indication)
16.2.6 Rest-of-Europe
16.3 Asia-Pacific
16.3.1 China
16.3.1.1 China Liquid Biopsy Market (by Oncology Indication)
16.3.2 Japan
16.3.2.1 Japan Liquid Biopsy Market (by Oncology Indication)
16.4 India
16.4.1 India Liquid Biopsy Market (by Oncology Indication)
16.4.2 Australia
16.4.2.1 Australia Liquid Biopsy Market (by Oncology Indication)
16.4.3 South Korea
16.4.3.1 South Korea Liquid Biopsy Market (by Oncology Indication)
16.4.4 Singapore
16.4.4.1 Singapore Liquid Biopsy Market (by Oncology Indication)
16.5 Rest-of-Asia-Pacific
16.6 Latin America and Middle East
16.6.1 Brazil
16.6.1.1 Brazil Liquid Biopsy Market (by Oncology Indication)
16.6.2 Mexico
16.6.2.1 Mexico Liquid Biopsy Market (by Oncology Indication)
16.6.3 Saudi Arabia
16.6.3.1 Saudi Arabia Liquid Biopsy Market (by Oncology Indication)
16.6.4 Rest-of-Latin America and Middle East
16.7 Rest-of-the-World
17 COMPANY PROFILES
17.1 Overview
17.2 Abcodia Ltd.
17.2.1 Company Overview
17.2.2 Role of Abcodia Ltd. in the Liquid Biopsy Market
17.2.3 SWOT Analysis
17.3 Biocept, Inc.
17.3.1 Company Overview
17.3.2 Role of Biocept, Inc. in Liquid Biopsy Market
17.3.3 Financials
17.3.4 Key Insights About Financial Health of the Company
17.3.5 SWOT Analysis
17.4 Bio-Rad Laboratories, Inc.
17.4.1 Company Overview
17.4.2 Role of Bio-Rad Laboratories, Inc. in Liquid Biopsy Market
17.4.3 Financials
17.4.4 Key Insights About Financial Health of the Company
17.4.5 SWOT Analysis
17.5 Cynvenio Biosystems, Inc.
17.5.1 Company Overview
17.5.2 Role of Cynvenio Biosystems, Inc. in the Liquid Biopsy Market
17.5.3 SWOT Analysis
17.6 Chronix Biomedical
17.6.1 Company Overview
17.6.2 Role of Chronix Biomedical in the Liquid Biopsy Market
17.6.3 SWOT Analysis
17.7 Epic Sciences, Inc.
17.7.1 Company Overview
17.7.2 Role of Epic Sciences, Inc. in the Liquid Biopsy in the Market
17.7.3 SWOT Analysis
17.8 F. Hoffmann-La Roche AG
17.8.1 Company Overview
17.8.2 Role of F. Hoffmann-La Roche AG in the Liquid Biopsy Market
17.8.3 Financials
17.8.4 Key Insights About Financial Health of the Company
17.8.5 SWOT Analysis
17.9 GUARDANT HEALTH, INC
17.9.1 Company Overview
17.9.2 Role of GUARDANT HEALTH, Inc. in Liquid Biopsy Market
17.9.3 Financials
17.9.4 Key Insights About Financial Health of the Company
17.9.5 Early Detection Strategy
17.9.5.1 Targeting Asymptomatic Population
17.9.5.2 Pilot Data on LUNAR-2 Lung Sensitivity by Stage
17.9.6 SWOT Analysis
17.10 Illumina, Inc.
17.10.1 Company Overview
17.10.2 Role of Illumina, Inc. in the Liquid Biopsy Market
17.10.3 Financials
17.10.4 Key Insights About Financial Health of the Company
17.10.5 SWOT Analysis
17.11 Menarini Silicon Biosystems, Inc.
17.11.1 Company Overview
17.11.2 Role of Menarini Silicon Biosystems in the Liquid Biopsy Market
17.11.3 SWOT Analysis
17.12 NeoGenomics Laboratories, Inc.
17.12.1 Company Overview
17.12.2 Role of NeoGenomics Laboratories, Inc. in the Liquid Biopsy Market
17.12.3 Financials
17.12.4 Key Insights About Financial Health of the Company
17.12.5 SWOT Analysis
17.13 Personal Genome Diagnostics, Inc.
17.13.1 Company Overview
17.13.2 Role of Personal Genome Diagnostics in the Liquid Biopsy Market
17.13.3 SWOT Analysis
17.14 Qiagen N.V.
17.14.1 Company Overview
17.14.2 Role of Qiagen N.V. in the Liquid Biopsy Market
17.14.3 Financials
17.14.4 Key Insights about Financial Health of the Company
17.14.5 SWOT Analysis
17.15 Resolution Bioscience, Inc.
17.15.1 Company Overview
17.15.2 Role of Resolution Biosciences, Inc. in the Liquid Biopsy Market
17.15.3 SWOT Analysis
17.16 Thermo Fisher Scientific
17.16.1 Company Overview
17.16.2 Role of Thermo Fisher Scientific in the Liquid Biopsy Market
17.16.3 Financials
17.16.4 Key Insights About Financial Health of the Company
17.16.5 SWOT Analysis
17.17 Exact Sciences Corporation
17.17.1 Company Overview
17.17.2 Role of Exact Sciences in the Global Liquid Biopsy Market
17.17.3 Financials
17.17.4 Key Insights About Financial Health of the Company
17.17.5 Early Detection Strategy
17.17.6 SWOT Analysis
17.18 Natera
17.18.1 Company Overview
17.18.2 Role of Natera Inc. in the Global Liquid Biopsy Market
17.18.3 Financials
17.18.4 Key Insights About Financial Health of the Company
17.18.5 SWOT Analysis
17.19 GRAIL
17.19.1 Company Overview
17.19.2 Role of GRAIL in the Liquid Biopsy Market
17.19.3 SWOT Analysis
17.20 Freenome
17.20.1 Company Overview
17.20.2 Role of Freenome in the Liquid Biopsy Market
17.20.3 SWOT Analysis
17.21 Thrive Earlier Detection
17.21.1 Company Overview
17.21.2 Role of Thrive Earlier Detection in the Liquid Biopsy Market
17.21.3 SWOT Analysis
LIST OF TABLES
Table 1: Most Common Cancers
Table 2: Existing Patients Issues with Standard Tissue Biopsies and Surgical Procedures
Table 4.1: Global Liquid Biopsy Market, by Region, ($Million), 2019-2030
Table 4.2: Comparative Analysis of Liquid Biopsy vs. Tissue Biopsy
Table 4.3: Comparative Analysis of Liquid Biopsy Technologies
Table 5.1: Approved Liquid Biopsy Test Kits from Major Players
Table 5.2: 12. List of Other Non-EGFR Liquid Biopsies Kits
Table 5.3: 12. List of Major Players Liquid Biopsies
Table 5.4: Elements for the Liquid Biopsy Regulatory Submission
Table 5.5: Reimbursement Scenario for Key Players Offerings in Global Liquid Biopsy Market
Table 5.6: Reimbursement Landscaping for Liquid Biopsies (FY2015-FY2019)
Table 5.7: Global Liquid Biopsy Market (Key Players Patent Portfolio)
Table 5.8: Investment Heat Map
Table 5.9: Investors Heat Map
Table 5.10: Liquid Biopsy Product Mapping Analysis (by Technology Type)
Table 5.11: Liquid Biopsy Product Mapping Analysis (by Sample Type)
Table 5.12: Liquid Biopsy Product Mapping Analysis by Biomarker
Table 5.13: Liquid Biopsy Product Mapping Analysis by Application
Table 5.14: Government Initiatives for Liquid Biopsies
Table 6.1: Pricing 12. List of Key Players Liquid Biopsies
Table 13.1: Comparison between the applications of ctDNA, CTCs, and exosomes
Table 16.1: Type-Specific Prevalence of Cancers in the U.S
Table 16.2: Type-specific Prevalence of Cancers in Canada
Table 16.3: Type-Specific Prevalence of Cancers in Germany
Table 16.4: Type-Specific Prevalence of Cancers in France
Table 16.5: Type-Specific Prevalence of Cancers in the U.K
Table 16.6: Type-specific Prevalence of Cancers in Italy
Table 16.7: Type-Specific Prevalence of Cancers in Spain
Table 16.8: Type-Specific Prevalence of Cancers in China
Table 16.9: Type-Specific Prevalence of Cancers in Japan
Table 16.10: Type-Specific Prevalence of Cancers in India
Table 16.11: Type-Specific Prevalence of Cancers in Australia
Table 16.12: Type-Specific Prevalence of Cancers in South Korea
Table 16.13: Type-Specific Prevalence of Cancers in Singapore
Table 16.14: Type-Specific Prevalence of Cancers in Brazil
Table 16.15: Type-specific Prevalence of Cancers in Mexico
Table 16.16: Type-Specific Prevalence of Cancers in Saudi Arabia
Table 1: Most Common Cancers
Table 2: Existing Patients Issues with Standard Tissue Biopsies and Surgical Procedures
Table 4.1: Global Liquid Biopsy Market, by Region, ($Million), 2019-2030
Table 4.2: Comparative Analysis of Liquid Biopsy vs. Tissue Biopsy
Table 4.3: Comparative Analysis of Liquid Biopsy Technologies
Table 5.1: Approved Liquid Biopsy Test Kits from Major Players
Table 5.2: 12. List of Other Non-EGFR Liquid Biopsies Kits
Table 5.3: 12. List of Major Players Liquid Biopsies
Table 5.4: Elements for the Liquid Biopsy Regulatory Submission
Table 5.5: Reimbursement Scenario for Key Players Offerings in Global Liquid Biopsy Market
Table 5.6: Reimbursement Landscaping for Liquid Biopsies (FY2015-FY2019)
Table 5.7: Global Liquid Biopsy Market (Key Players Patent Portfolio)
Table 5.8: Investment Heat Map
Table 5.9: Investors Heat Map
Table 5.10: Liquid Biopsy Product Mapping Analysis (by Technology Type)
Table 5.11: Liquid Biopsy Product Mapping Analysis (by Sample Type)
Table 5.12: Liquid Biopsy Product Mapping Analysis by Biomarker
Table 5.13: Liquid Biopsy Product Mapping Analysis by Application
Table 5.14: Government Initiatives for Liquid Biopsies
Table 6.1: Pricing 12. List of Key Players Liquid Biopsies
Table 13.1: Comparison between the applications of ctDNA, CTCs, and exosomes
Table 16.1: Type-Specific Prevalence of Cancers in the U.S
Table 16.2: Type-specific Prevalence of Cancers in Canada
Table 16.3: Type-Specific Prevalence of Cancers in Germany
Table 16.4: Type-Specific Prevalence of Cancers in France
Table 16.5: Type-Specific Prevalence of Cancers in the U.K
Table 16.6: Type-specific Prevalence of Cancers in Italy
Table 16.7: Type-Specific Prevalence of Cancers in Spain
Table 16.8: Type-Specific Prevalence of Cancers in China
Table 16.9: Type-Specific Prevalence of Cancers in Japan
Table 16.10: Type-Specific Prevalence of Cancers in India
Table 16.11: Type-Specific Prevalence of Cancers in Australia
Table 16.12: Type-Specific Prevalence of Cancers in South Korea
Table 16.13: Type-Specific Prevalence of Cancers in Singapore
Table 16.14: Type-Specific Prevalence of Cancers in Brazil
Table 16.15: Type-specific Prevalence of Cancers in Mexico
Table 16.16: Type-Specific Prevalence of Cancers in Saudi Arabia
LIST OF FIGURES
Figure 1: Type of Cancer Diagnostics
Figure 2: Considerations for Liquid Biopsy
Figure 3: Impact Analysis of Market Drivers and Market Challenges on the Global Liquid Biopsy Market
Figure 4: Global Liquid Biopsy Market (by Technology), $Million, 2020 and 2030
Figure 5: Global Liquid Biopsy Market (by Workflow), $Million, 2020 and 2030
Figure 6: Global Liquid Biopsy Market (by Usage), $Million, 2020 and 2030
Figure 7: Global Liquid Biopsy Market (by Type of Sample), $Million, 2020 and 2030
Figure 8: Global Liquid Biopsy Market (by Circulating Biomarkers), $Million, 2020 and 2030
Figure 9: Global Liquid Biopsy Market (by Products), $Million, 2020 and 2030
Figure 10: Global Liquid Biopsy Market (by Indication), $Million, 2020 and 2030
Figure 11: Global Liquid Biopsy Market (by Clinical Application), $Million, 2020 and 2030
Figure 12: Global Liquid Biopsy Market (by Region), $Million, 2019
Figure 2.1: Global Liquid Biopsy Market Segmentation
Figure 3.1: Global Liquid Biopsy Market Research Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Global Liquid Biopsy Market, 2019-2030 ($Million)
Figure 4.2: Historical Evolution of Liquid Biopsy Testing
Figure 5.1: Key Findings from Liquid Biopsy Reimbursement Study
Figure 5.2: Liquid Biopsy Market, Percent Split of Filed Patients (FY2014-FY2018)
Figure 5.3: Liquid Biopsy Patent Analysis (FY2014-FY2018)
Figure 5.4: Patent Expiration Analysis
Figure 5.5: Key Players Financing Stratification
Figure 5.6: Financing Analysis (FY2017-FY2019), US$ Million
Figure 5.7: Liquid Biopsies Key Players Financing Analysis
Figure 5.8: Liquid Biopsy Supply Chain Analysis
Figure 5.9: Physicians Perceptions for Liquid Biopsies
Figure 5.10: Investors Perception
Figure 5.11: Recent Government Initiatives to Debunk the Negative Impact of COVID-19 on Liquid Biopsy Industry
Figure 5.12: Impact of COVID-19 on Liquid Biopsy Testing Industry
Figure 5.13: Implication of COVID-19 on Liquid Biopsy Testing Landscape
Figure 5.14: Key Liquid Biopsy Testing Players
Figure 5.15: Challenges Faced by Liquid Biopsy Key Players due to COVID-19
Figure 5.16: Steps to Mitigate the Impact on COVID-19 on Liquid Biopsy Testing Industry
Figure 6.1: Market Dynamics of Global Liquid Biopsy Market
Figure 6.2: Cancer Prevalence Trends**, (2013-2017)
Figure 6.3: Synergistic Activities, 2018-2019
Figure 6.4: SBIR and STTR Grants and Contract Funding 2008-2018
Figure 6.5: NCI Fiscal Budget Year on Year, 2013-2018
Figure 6.6: Case Scenario: NSCLC Liquid Biopsy Coverage Status of Payors
Figure 7.1: Share of Key Developments and Strategies, January 2017-January 2019
Figure 7.2: Synergistic Activities Share (by Company), January 2017-December 2019
Figure 7.3: Accreditations Share (by Company), January 2017-December 2019
Figure 7.4: Product and Service Launches Share (by Company), January 2017- December 2019
Figure 7.5: Mergers and Acquisitions (by Company), January 2017-December 2019
Figure 7.6: Regulatory Approvals (by Company), January 2017-December 2019
Figure 7.7: Global Liquid Biopsy Market Share Analysis 2018 Vs 2019
Figure 7.8: Growth Share Matrix for Global Liquid Biopsy Market (by Company), 2019
Figure 7.9: Growth Share Matrix for Global Liquid Biopsy Market (by Technology), 2019
Figure 7.10: Growth Share Analysis (by Indication), 2019
Figure 7.11: Growth Share Analysis (by Biomarker Type), 2019
Figure 7.12: Growth Share Analysis (by Clinical Application), 2019
Figure 8.1: Global Liquid Biopsy Market (by Product), 2020 vs. 2030
Figure 8.2: Global Liquid Biopsy Market (by Test/Service), 2019-2030
Figure 8.3: Global Liquid Biopsy Market (by Kits and Consumables), 2019-2030
Figure 8.4: Global Liquid Biopsy Market (by Instruments), 2019-2030
Figure 9.1: Global Liquid Biopsy Market (by Technology), 2020 vs. 2030
Figure 9.2: Global Liquid Biopsy Market (by Next Generation Sequencing), 2019-2030
Figure 9.3: Global Liquid Biopsy Market (by Polymerase Chain Reaction), 2019-2030
Figure 9.4: Global Liquid Biopsy Market (by Digital PCR Technology), 2019-2030
Figure 9.5: Global Liquid Biopsy Market (by Multiplex PCR Technology), 2019-2030
Figure 9.6: Global Liquid Biopsy Market (by Real-Time PCR Technology), 2019-2030
Figure 9.7: Global Liquid Biopsy Market (by Other PCR Technologies), 2019-2030
Figure 9.8: Global Liquid Biopsy Market (by FISH), 2019-2030
Figure 9.9: Global Liquid Biopsy Market (by Other Technologies), 2019-2030
Figure 10.1: Global Liquid Biopsy Market (by Workflow), 2020 Vs. 2030
Figure 10.2: Global Liquid Biopsy Market (by Sample Preparation Segment), 2019-2030
Figure 10.3: Global Liquid Biopsy Market (by Library Preparation Segment), 2019-2030
Figure 10.4: Global Liquid Biopsy Market (by Sequencing Segment), 2019-2030
Figure 10.5: Global Liquid Biopsy Market (by Data Analysis and Management Segment), 2019-2030
Figure 11.1: Global Liquid Biopsy Market (by Usage), 2020 vs. 2030
Figure 11.2: Global Liquid Biopsy Market (by Clinical Applications), 2019-2030
Figure 11.3: Global Liquid Biopsy Market (by Research Applications), 2019-2030
Figure 12.1: Global Liquid Biopsy Market (by Type of Sample), 2020 vs. 2030
Figure 12.2: Global Liquid Biopsy Market (by Blood Sample), 2019-2030
Figure 12.3: Global Liquid Biopsy Market (by Urine), 2019-2030
Figure 12.4: Global Liquid Biopsy Market (by Saliva), 2019-2030
Figure 12.5: Global Liquid Biopsy Market (by Cerebrospinal Fluid), 2019-2030
Figure 13.1: Global Liquid Biopsy Market (by Circulating Biomarkers), 2020 vs. 2030
Figure 13.2: Global Liquid Biopsy Market (by Circulating Tumor Cells), 2019-2030
Figure 13.3: Global Liquid Biopsy Market (by Cell-Free DNA), 2019-2030
Figure 13.4: Global Liquid Biopsy Market (by Circulating Cell-Free RNA), 2019-2030
Figure 13.5: Global Liquid Biopsy Market (by Exosomes and Extracellular Vesicles), 2019-2030
Figure 13.6: Global Liquid Biopsy Market (by Other Biomarkers), 2019-2030
Figure 14.1: Global Liquid Biopsy Market (by Indication)
Figure 14.2: Global Liquid Biopsy Market (by Indication), 2020 vs. 2030
Figure 14.3: Global Liquid Biopsy Market (by Lung Cancer), 2019-2030
Figure 14.4: Global Liquid Biopsy Market (by Breast Cancer), 2019-2030
Figure 14.5: Global Liquid Biopsy Market (by Prostate Cancer), 2019-2030
Figure 14.6: Global Liquid Biopsy Market (by Colorectal Cancer), 2019-2030
Figure 14.7: Global Liquid Biopsy Market (by Melanoma), 2019-2030
Figure 14.8: Global Liquid Biopsy Market (by Other Type of Cancers), 2019-2030
Figure 14.9: Global Liquid Biopsy Market (by Non-Oncology Disorders), 2019-2030
Figure 15.1: Global Liquid Biopsy Market (by Clinical Application), 2020 vs. 2030
Figure 15.2: Global Liquid Biopsy Market (by Treatment Monitoring), 2019-2030
Figure 15.3: Global Liquid Biopsy Market (by Prognosis and Recurrence Monitoring), 2019-2030
Figure 15.4: Global Liquid Biopsy Market (by Treatment Selection), 2019-2030
Figure 15.5: Global Liquid Biopsy Market (by Diagnosis and Screening), 2019-2030
Figure 16.1: Global Liquid Biopsy Market (by Region), 2020 vs. 2030
Figure 16.2: Global Liquid Biopsy Market (by North America), 2020-2030
Figure 16.3: Market Dynamics of North American Liquid Biopsy Market
Figure 16.4: U.S. Liquid Biopsy Market, 2019-2030
Figure 16.5: Cancer Prevalence Trends in the U.S (2013-2017)
Figure 16.6: U.S Liquid Biopsy Market (by Oncology Indications), 2019-2030
Figure 16.7: U.S Liquid Biopsy Market (by Type of Cancer)
Figure 16.8: Canada Liquid Biopsy Market, 2019-2030
Figure 16.9: Cancer Prevalence Trends in Canada (2013-2017)
Figure 16.10: Canada Liquid Biopsy Market (by Oncology Indications), 2019-2030
Figure 16.11: Canada Liquid Biopsy Market (by Types of Cancers)
Figure 16.12: Global Liquid Biopsy Market (by Europe), 2020 vs. 2030
Figure 16.13: Market Dynamics of European Liquid Biopsy Market
Figure 16.14: Germany Liquid Biopsy Market, 2019-2030
Figure 16.15: Cancer Prevalence Trends in Germany (2013-2017)
Figure 16.16: Germany Liquid Biopsy Market (by Oncology Indication), 2019-2030
Figure 16.17: Germany Liquid Biopsy Market by Type of Cancers
Figure 16.18: France Liquid Biopsy Market, 2019-2030
Figure 16.19: Cancer Prevalence Trends in France (2013-2017)
Figure 16.20: France Liquid Biopsy Market (by Oncology Indications), 2019-2030
Figure 16.21: France Liquid Biopsy Market by Type of Cancers
Figure 16.22: U.K. Liquid Biopsy Market, 2019-2030
Figure 16.23: Cancer Prevalence Trends in the U.K. (2013-2017)
Figure 16.24: The U.K Liquid Biopsy Market, (by Oncology Indications), 2019-2030
Figure 16.25: U.K. Liquid Biopsy Market by Type of Cancers
Figure 16.26: Italy Liquid Biopsy Market, 2019-2030
Figure 16.27: Cancer Prevalence Trends in Italy (2013-2017)
Figure 16.28: Italy Liquid Biopsy Market, (by Oncology Indications), 2019-2030
Figure 16.29: Italy Liquid Biopsy Market by Type of Cancers
Figure 16.30: Spain Liquid Biopsy Market, 2019-2030
Figure 16.31: Cancer Prevalence Trends in Spain (2013-2017)
Figure 16.32: Spain Liquid Biopsy Market, (by Oncology Indications), 2019-2030
Figure 16.33: Spain Liquid Biopsy Market by Type of Cancers
Figure 16.34: Rest-of-Europe Liquid Biopsy Market, 2019-2030
Figure 16.35: Asia-Pacific Liquid Biopsy Market, 2020 vs. 2030
Figure 16.36: Market Dynamics of Asia-Pacific Liquid Biopsy Market
Figure 16.37: China Liquid Biopsy Market, 2019-2030
Figure 16.38: Cancer Prevalence Trends in China (2013-2017)
Figure 16.39: China Liquid Biopsy Market (by Oncology Indication), 2019-2030
Figure 16.40: China Liquid Biopsy Market by Types of Cancer
Figure 16.41: Japan Liquid Biopsy Market, 2019-2030
Figure 16.42: Cancer Prevalence Trends in Japan (2013-2017)
Figure 16.43: Japan Liquid Biopsy Market (by Oncology Indications), 2019-2030
Figure 16.44: Japan Liquid Biopsy Market by Types of Cancer
Figure 16.45 India Liquid Biopsy Market, 2019-2030
Figure 16.46: Cancer Prevalence Trends in India (2013-2017)
Figure 16.47: India Liquid Biopsy Market (by Oncology Indications), 2019-2030
Figure 16.48: India Liquid Biopsy Market by Type of Cancers
Figure 16.49: Australia Liquid Biopsy Market, 2019-2030
Figure 16.50: Cancer Prevalence Trends in Australia (2013-2017)
Figure 16.51: Australia Liquid Biopsy Market, (by Oncology Indications), 2019-2030
Figure 16.52: Australia Liquid Biopsy Market by Types of Cancer
Figure 16.53: South Korea Liquid Biopsy Market, 2019-2030
Figure 16.54: Cancer Prevalence Trends in South Korea (2013-2017)
Figure 16.55: South Korea Liquid Biopsy Market, (by Oncology Indications), 2019-2030
Figure 16.56: South Korea Liquid Biopsy Market by Types of Cancer
Figure 16.57: Singapore Liquid Biopsy Market, 2019-2030
Figure 16.58: Cancer Prevalence Trends in Singapore (2013-2017)
Figure 16.59: Singapore Liquid Biopsy Market, (by Oncology Indication), 2019-2030
Figure 16.60: Singapore Liquid Biopsy Market by Type of Cancers
Figure 16.61: Rest-of-Asia-Pacific Liquid Biopsy Market, 2019-2030
Figure 16.62: Latin-America and Middle East Liquid Biopsy Market, 2020 vs. 2030
Figure 16.63: Market Dynamics of Latin America and Middle Eastern Liquid Biopsy Market
Figure 16.64: Brazil Liquid Biopsy Market, 2019-2030
Figure 16.65: Cancer Prevalence Trends in Brazil (2013-2017)
Figure 16.66: Brazil Liquid Biopsy Market (by Oncology Indication), 2019-2030
Figure 16.67: Brazil Liquid Biopsy Market by Type of Cancers
Figure 16.68: Mexico Liquid Biopsy Market, 2019-2030
Figure 16.69: Cancer Prevalence Trends in Mexico (2013-2017)
Figure 16.70: Mexico Liquid Biopsy Market (by Oncology Indications), 2019-2030
Figure 16.71: Mexico Liquid Biopsy Market by Types of Cancer
Figure 16.72: Saudi Arabia Liquid Biopsy Market, 2019-2030
Figure 16.73: Cancer Prevalence Trends in Saudi Arabia (2013-2017)
Figure 16.74: Saudi Arabia Liquid Biopsy Market (by Oncology Indication), 2019-2030
Figure 16.75: Saudi Arabia Liquid Biopsy Market by Types of Cancer
Figure 16.76: Rest-of-Latin America and Middle East Liquid Biopsy Market, 2019-2030
Figure 16.77: Rest-of-the-World Liquid Biopsy Market, 2019-2030
Figure 17.1: Total Number of Companies Profiled
Figure 17.2: Abcodia Product Portfolio
Figure 17.3: SWOT Analysis: Abcodia Ltd.
Figure 17.4: Biocept, Inc.: Portfolio
Figure 17.5: Biocept Inc.: Overall Financials, 2017-2019
Figure 17.6: Biocept, Inc.: R&D Expenditure, 2017-2019
Figure 17.7: SWOT Analysis: Biocept Inc
Figure 17.8: Bio-Rad Laboratories, Inc.: Portfolio
Figure 17.9: Bio-Rad Laboratories, Inc.: Overall Financials, 2017-2019
Figure 17.10: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2017-2019
Figure 17.11: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2017-2019
Figure 17.12: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2017-2019
Figure 17.13: SWOT Analysis: Bio-Rad Laboratories Inc.
Figure 17.14: Cynvenio Biosystems: Portfolio
Figure 17.15: SWOT Analysis: Cynvenio Biosystems Inc.
Figure 17.16: Chronix Biomedical: Portfolio
Figure 17.17: SWOT Analysis: Chronix Biomedical
Figure 17.18: Epic Sciences: Portfolio
Figure 17.19: SWOT Analysis: Epic Sciences
Figure 17.20: F. Hoffmann-La Roche Ltd: Portfolio
Figure 17.21: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
Figure 17.22: F. Hoffmann-La Roche Ltd: Sales (by Segment), 2017-2019
Figure 17.23: F. Hoffmann-La Roche Ltd: Sales (by Region), 2017-2019
Figure 17.24: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
Figure 17.25: SWOT Analysis: F. Hoffmann-La Roche Ltd.
Figure 17.26: Guardant Health: Portfolio
Figure 17.27: Guardant Health: Overall Financials, 2017-2019
Figure 17.28: Guardant Health: Sales (by Segment), 2017-2019
Figure 17.29 Guardant Health: Sales (by Region), 2017-2019
Figure 17.30: Guardant Health: R&D Expenditure, 2017-2019
Figure 17.31: SWOT Analysis: Guardant Health Inc.
Figure 17.32: Illumina Inc. Portfolio
Figure 17.33: Illumina, Inc.: Overall Financials, 2017-2019
Figure 17.34: Illumina, Inc.: Revenue (by Segment), 2017-2019
Figure 17.35: Illumina, Inc.: Revenue (by Region), 2017-2019
Figure 17.36: Illumina, Inc.: R&D Expenditure, 2017-2019
Figure 17.37: SWOT Analysis: Illumina Inc.
Figure 17.38: Menarini Silicon Biosystems: Portfolio
Figure 17.39: SWOT Analysis: Menarini Silicon Biosystems
Figure 17.40: Neogenomics Laboratories: Portfolio
Figure 17.41: NeoGenomics Laboratories, Inc.: Overall Financials, 2017-2019
Figure 17.42: NeoGenomics Laboratories, Inc.: Revenue (by Segment), 2017-2019
Figure 17.43: NeoGenomics Laboratories, Inc.: R&D Expenditure, 2017-2019
Figure 17.44: SWOT Analysis: Neogenomics Laboratories
Figure 17.45: Personal Genome Diagnostics: Portfolio
Figure 17.46: SWOT Analysis: Personal Genome Diagnostics
Figure 17.47: QIAGEN N.V.: Portfolio
Figure 17.48: QIAGEN N.V.: Overall Financials, 2017-2019
Figure 17.49: QIAGEN N.V.: Revenue (by Segment), 2017-2019
Figure 17.50: QIAGEN N.V.: Revenue (by Region), 2017-2019
Figure 17.51: QIAGEN N.V.: R&D Expenditure, 2017-2019
Figure 17.52: SWOT Analysis: Qiagen N.V.
Figure 17.53: Resolution Biosciences: Portfolio
Figure 17.53: SWOT Analysis: Resolution Biosciences
Figure 17.54: Thermo Fisher Scientific: Portfolio
Figure 17.55: Thermo Fisher Scientific Inc.: Overall Financials, 2017-2019
Figure 17.56: Thermo Fisher Scientific Inc: Sales (by Segment), $Million, 2017-2019
Figure 17.57: Thermo Fisher Scientific Inc.: Sales (by Region), 2017-2019
Figure 17.58: Thermo Fisher Scientific Inc.: R&D Expenditure, 2017-2019
Figure 17.59: SWOT Analysis: Thermo Fisher Scientific Inc.
Figure 10.41: Exact Sciences: Portfolio
Figure 17.60: Exact Sciences Corporation: Overall Financials, 2017-2019
Figure 17.61: Exact Sciences Corporation: Sales (by Segment), $Million, 2017-2019
Figure 17.62: Exact Sciences Corporation.: Sales (by Region), 2017-2019
Figure 17.63: Exact Sciences Corporation: R&D Expenditure, 2017-2019
Figure 17.64: SWOT Analysis: Exact Sciences Corporation
Figure 17.65: Natera Inc.Product Portfolio.
Figure 17.66: Natera Inc: Overall Financials, 2017-2019
Figure 17.67: Natera Inc.: Sales (by Segment), $Million, 2017-2019
Figure 17.68: Exact Sciences Corporation.: Sales (by Region), 2017-2019
Figure 17.69: Natera Inc.: R&D Expenditure, 2017-2019
Figure 17.70: SWOT Analysis: Natera Inc.
Figure 17.71: GRAIL: Portfolio
Figure 17.72: SWOT Analysis: GRAIL
Figure 17.73: Freenome: Portfolio
Figure 17.74: SWOT Analysis: Freenome
Figure 17.75: Thrive Earlier Detection: Portfolio
Figure 17.76: SWOT Analysis: Thrive Earlier Detection
Figure 1: Type of Cancer Diagnostics
Figure 2: Considerations for Liquid Biopsy
Figure 3: Impact Analysis of Market Drivers and Market Challenges on the Global Liquid Biopsy Market
Figure 4: Global Liquid Biopsy Market (by Technology), $Million, 2020 and 2030
Figure 5: Global Liquid Biopsy Market (by Workflow), $Million, 2020 and 2030
Figure 6: Global Liquid Biopsy Market (by Usage), $Million, 2020 and 2030
Figure 7: Global Liquid Biopsy Market (by Type of Sample), $Million, 2020 and 2030
Figure 8: Global Liquid Biopsy Market (by Circulating Biomarkers), $Million, 2020 and 2030
Figure 9: Global Liquid Biopsy Market (by Products), $Million, 2020 and 2030
Figure 10: Global Liquid Biopsy Market (by Indication), $Million, 2020 and 2030
Figure 11: Global Liquid Biopsy Market (by Clinical Application), $Million, 2020 and 2030
Figure 12: Global Liquid Biopsy Market (by Region), $Million, 2019
Figure 2.1: Global Liquid Biopsy Market Segmentation
Figure 3.1: Global Liquid Biopsy Market Research Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Global Liquid Biopsy Market, 2019-2030 ($Million)
Figure 4.2: Historical Evolution of Liquid Biopsy Testing
Figure 5.1: Key Findings from Liquid Biopsy Reimbursement Study
Figure 5.2: Liquid Biopsy Market, Percent Split of Filed Patients (FY2014-FY2018)
Figure 5.3: Liquid Biopsy Patent Analysis (FY2014-FY2018)
Figure 5.4: Patent Expiration Analysis
Figure 5.5: Key Players Financing Stratification
Figure 5.6: Financing Analysis (FY2017-FY2019), US$ Million
Figure 5.7: Liquid Biopsies Key Players Financing Analysis
Figure 5.8: Liquid Biopsy Supply Chain Analysis
Figure 5.9: Physicians Perceptions for Liquid Biopsies
Figure 5.10: Investors Perception
Figure 5.11: Recent Government Initiatives to Debunk the Negative Impact of COVID-19 on Liquid Biopsy Industry
Figure 5.12: Impact of COVID-19 on Liquid Biopsy Testing Industry
Figure 5.13: Implication of COVID-19 on Liquid Biopsy Testing Landscape
Figure 5.14: Key Liquid Biopsy Testing Players
Figure 5.15: Challenges Faced by Liquid Biopsy Key Players due to COVID-19
Figure 5.16: Steps to Mitigate the Impact on COVID-19 on Liquid Biopsy Testing Industry
Figure 6.1: Market Dynamics of Global Liquid Biopsy Market
Figure 6.2: Cancer Prevalence Trends**, (2013-2017)
Figure 6.3: Synergistic Activities, 2018-2019
Figure 6.4: SBIR and STTR Grants and Contract Funding 2008-2018
Figure 6.5: NCI Fiscal Budget Year on Year, 2013-2018
Figure 6.6: Case Scenario: NSCLC Liquid Biopsy Coverage Status of Payors
Figure 7.1: Share of Key Developments and Strategies, January 2017-January 2019
Figure 7.2: Synergistic Activities Share (by Company), January 2017-December 2019
Figure 7.3: Accreditations Share (by Company), January 2017-December 2019
Figure 7.4: Product and Service Launches Share (by Company), January 2017- December 2019
Figure 7.5: Mergers and Acquisitions (by Company), January 2017-December 2019
Figure 7.6: Regulatory Approvals (by Company), January 2017-December 2019
Figure 7.7: Global Liquid Biopsy Market Share Analysis 2018 Vs 2019
Figure 7.8: Growth Share Matrix for Global Liquid Biopsy Market (by Company), 2019
Figure 7.9: Growth Share Matrix for Global Liquid Biopsy Market (by Technology), 2019
Figure 7.10: Growth Share Analysis (by Indication), 2019
Figure 7.11: Growth Share Analysis (by Biomarker Type), 2019
Figure 7.12: Growth Share Analysis (by Clinical Application), 2019
Figure 8.1: Global Liquid Biopsy Market (by Product), 2020 vs. 2030
Figure 8.2: Global Liquid Biopsy Market (by Test/Service), 2019-2030
Figure 8.3: Global Liquid Biopsy Market (by Kits and Consumables), 2019-2030
Figure 8.4: Global Liquid Biopsy Market (by Instruments), 2019-2030
Figure 9.1: Global Liquid Biopsy Market (by Technology), 2020 vs. 2030
Figure 9.2: Global Liquid Biopsy Market (by Next Generation Sequencing), 2019-2030
Figure 9.3: Global Liquid Biopsy Market (by Polymerase Chain Reaction), 2019-2030
Figure 9.4: Global Liquid Biopsy Market (by Digital PCR Technology), 2019-2030
Figure 9.5: Global Liquid Biopsy Market (by Multiplex PCR Technology), 2019-2030
Figure 9.6: Global Liquid Biopsy Market (by Real-Time PCR Technology), 2019-2030
Figure 9.7: Global Liquid Biopsy Market (by Other PCR Technologies), 2019-2030
Figure 9.8: Global Liquid Biopsy Market (by FISH), 2019-2030
Figure 9.9: Global Liquid Biopsy Market (by Other Technologies), 2019-2030
Figure 10.1: Global Liquid Biopsy Market (by Workflow), 2020 Vs. 2030
Figure 10.2: Global Liquid Biopsy Market (by Sample Preparation Segment), 2019-2030
Figure 10.3: Global Liquid Biopsy Market (by Library Preparation Segment), 2019-2030
Figure 10.4: Global Liquid Biopsy Market (by Sequencing Segment), 2019-2030
Figure 10.5: Global Liquid Biopsy Market (by Data Analysis and Management Segment), 2019-2030
Figure 11.1: Global Liquid Biopsy Market (by Usage), 2020 vs. 2030
Figure 11.2: Global Liquid Biopsy Market (by Clinical Applications), 2019-2030
Figure 11.3: Global Liquid Biopsy Market (by Research Applications), 2019-2030
Figure 12.1: Global Liquid Biopsy Market (by Type of Sample), 2020 vs. 2030
Figure 12.2: Global Liquid Biopsy Market (by Blood Sample), 2019-2030
Figure 12.3: Global Liquid Biopsy Market (by Urine), 2019-2030
Figure 12.4: Global Liquid Biopsy Market (by Saliva), 2019-2030
Figure 12.5: Global Liquid Biopsy Market (by Cerebrospinal Fluid), 2019-2030
Figure 13.1: Global Liquid Biopsy Market (by Circulating Biomarkers), 2020 vs. 2030
Figure 13.2: Global Liquid Biopsy Market (by Circulating Tumor Cells), 2019-2030
Figure 13.3: Global Liquid Biopsy Market (by Cell-Free DNA), 2019-2030
Figure 13.4: Global Liquid Biopsy Market (by Circulating Cell-Free RNA), 2019-2030
Figure 13.5: Global Liquid Biopsy Market (by Exosomes and Extracellular Vesicles), 2019-2030
Figure 13.6: Global Liquid Biopsy Market (by Other Biomarkers), 2019-2030
Figure 14.1: Global Liquid Biopsy Market (by Indication)
Figure 14.2: Global Liquid Biopsy Market (by Indication), 2020 vs. 2030
Figure 14.3: Global Liquid Biopsy Market (by Lung Cancer), 2019-2030
Figure 14.4: Global Liquid Biopsy Market (by Breast Cancer), 2019-2030
Figure 14.5: Global Liquid Biopsy Market (by Prostate Cancer), 2019-2030
Figure 14.6: Global Liquid Biopsy Market (by Colorectal Cancer), 2019-2030
Figure 14.7: Global Liquid Biopsy Market (by Melanoma), 2019-2030
Figure 14.8: Global Liquid Biopsy Market (by Other Type of Cancers), 2019-2030
Figure 14.9: Global Liquid Biopsy Market (by Non-Oncology Disorders), 2019-2030
Figure 15.1: Global Liquid Biopsy Market (by Clinical Application), 2020 vs. 2030
Figure 15.2: Global Liquid Biopsy Market (by Treatment Monitoring), 2019-2030
Figure 15.3: Global Liquid Biopsy Market (by Prognosis and Recurrence Monitoring), 2019-2030
Figure 15.4: Global Liquid Biopsy Market (by Treatment Selection), 2019-2030
Figure 15.5: Global Liquid Biopsy Market (by Diagnosis and Screening), 2019-2030
Figure 16.1: Global Liquid Biopsy Market (by Region), 2020 vs. 2030
Figure 16.2: Global Liquid Biopsy Market (by North America), 2020-2030
Figure 16.3: Market Dynamics of North American Liquid Biopsy Market
Figure 16.4: U.S. Liquid Biopsy Market, 2019-2030
Figure 16.5: Cancer Prevalence Trends in the U.S (2013-2017)
Figure 16.6: U.S Liquid Biopsy Market (by Oncology Indications), 2019-2030
Figure 16.7: U.S Liquid Biopsy Market (by Type of Cancer)
Figure 16.8: Canada Liquid Biopsy Market, 2019-2030
Figure 16.9: Cancer Prevalence Trends in Canada (2013-2017)
Figure 16.10: Canada Liquid Biopsy Market (by Oncology Indications), 2019-2030
Figure 16.11: Canada Liquid Biopsy Market (by Types of Cancers)
Figure 16.12: Global Liquid Biopsy Market (by Europe), 2020 vs. 2030
Figure 16.13: Market Dynamics of European Liquid Biopsy Market
Figure 16.14: Germany Liquid Biopsy Market, 2019-2030
Figure 16.15: Cancer Prevalence Trends in Germany (2013-2017)
Figure 16.16: Germany Liquid Biopsy Market (by Oncology Indication), 2019-2030
Figure 16.17: Germany Liquid Biopsy Market by Type of Cancers
Figure 16.18: France Liquid Biopsy Market, 2019-2030
Figure 16.19: Cancer Prevalence Trends in France (2013-2017)
Figure 16.20: France Liquid Biopsy Market (by Oncology Indications), 2019-2030
Figure 16.21: France Liquid Biopsy Market by Type of Cancers
Figure 16.22: U.K. Liquid Biopsy Market, 2019-2030
Figure 16.23: Cancer Prevalence Trends in the U.K. (2013-2017)
Figure 16.24: The U.K Liquid Biopsy Market, (by Oncology Indications), 2019-2030
Figure 16.25: U.K. Liquid Biopsy Market by Type of Cancers
Figure 16.26: Italy Liquid Biopsy Market, 2019-2030
Figure 16.27: Cancer Prevalence Trends in Italy (2013-2017)
Figure 16.28: Italy Liquid Biopsy Market, (by Oncology Indications), 2019-2030
Figure 16.29: Italy Liquid Biopsy Market by Type of Cancers
Figure 16.30: Spain Liquid Biopsy Market, 2019-2030
Figure 16.31: Cancer Prevalence Trends in Spain (2013-2017)
Figure 16.32: Spain Liquid Biopsy Market, (by Oncology Indications), 2019-2030
Figure 16.33: Spain Liquid Biopsy Market by Type of Cancers
Figure 16.34: Rest-of-Europe Liquid Biopsy Market, 2019-2030
Figure 16.35: Asia-Pacific Liquid Biopsy Market, 2020 vs. 2030
Figure 16.36: Market Dynamics of Asia-Pacific Liquid Biopsy Market
Figure 16.37: China Liquid Biopsy Market, 2019-2030
Figure 16.38: Cancer Prevalence Trends in China (2013-2017)
Figure 16.39: China Liquid Biopsy Market (by Oncology Indication), 2019-2030
Figure 16.40: China Liquid Biopsy Market by Types of Cancer
Figure 16.41: Japan Liquid Biopsy Market, 2019-2030
Figure 16.42: Cancer Prevalence Trends in Japan (2013-2017)
Figure 16.43: Japan Liquid Biopsy Market (by Oncology Indications), 2019-2030
Figure 16.44: Japan Liquid Biopsy Market by Types of Cancer
Figure 16.45 India Liquid Biopsy Market, 2019-2030
Figure 16.46: Cancer Prevalence Trends in India (2013-2017)
Figure 16.47: India Liquid Biopsy Market (by Oncology Indications), 2019-2030
Figure 16.48: India Liquid Biopsy Market by Type of Cancers
Figure 16.49: Australia Liquid Biopsy Market, 2019-2030
Figure 16.50: Cancer Prevalence Trends in Australia (2013-2017)
Figure 16.51: Australia Liquid Biopsy Market, (by Oncology Indications), 2019-2030
Figure 16.52: Australia Liquid Biopsy Market by Types of Cancer
Figure 16.53: South Korea Liquid Biopsy Market, 2019-2030
Figure 16.54: Cancer Prevalence Trends in South Korea (2013-2017)
Figure 16.55: South Korea Liquid Biopsy Market, (by Oncology Indications), 2019-2030
Figure 16.56: South Korea Liquid Biopsy Market by Types of Cancer
Figure 16.57: Singapore Liquid Biopsy Market, 2019-2030
Figure 16.58: Cancer Prevalence Trends in Singapore (2013-2017)
Figure 16.59: Singapore Liquid Biopsy Market, (by Oncology Indication), 2019-2030
Figure 16.60: Singapore Liquid Biopsy Market by Type of Cancers
Figure 16.61: Rest-of-Asia-Pacific Liquid Biopsy Market, 2019-2030
Figure 16.62: Latin-America and Middle East Liquid Biopsy Market, 2020 vs. 2030
Figure 16.63: Market Dynamics of Latin America and Middle Eastern Liquid Biopsy Market
Figure 16.64: Brazil Liquid Biopsy Market, 2019-2030
Figure 16.65: Cancer Prevalence Trends in Brazil (2013-2017)
Figure 16.66: Brazil Liquid Biopsy Market (by Oncology Indication), 2019-2030
Figure 16.67: Brazil Liquid Biopsy Market by Type of Cancers
Figure 16.68: Mexico Liquid Biopsy Market, 2019-2030
Figure 16.69: Cancer Prevalence Trends in Mexico (2013-2017)
Figure 16.70: Mexico Liquid Biopsy Market (by Oncology Indications), 2019-2030
Figure 16.71: Mexico Liquid Biopsy Market by Types of Cancer
Figure 16.72: Saudi Arabia Liquid Biopsy Market, 2019-2030
Figure 16.73: Cancer Prevalence Trends in Saudi Arabia (2013-2017)
Figure 16.74: Saudi Arabia Liquid Biopsy Market (by Oncology Indication), 2019-2030
Figure 16.75: Saudi Arabia Liquid Biopsy Market by Types of Cancer
Figure 16.76: Rest-of-Latin America and Middle East Liquid Biopsy Market, 2019-2030
Figure 16.77: Rest-of-the-World Liquid Biopsy Market, 2019-2030
Figure 17.1: Total Number of Companies Profiled
Figure 17.2: Abcodia Product Portfolio
Figure 17.3: SWOT Analysis: Abcodia Ltd.
Figure 17.4: Biocept, Inc.: Portfolio
Figure 17.5: Biocept Inc.: Overall Financials, 2017-2019
Figure 17.6: Biocept, Inc.: R&D Expenditure, 2017-2019
Figure 17.7: SWOT Analysis: Biocept Inc
Figure 17.8: Bio-Rad Laboratories, Inc.: Portfolio
Figure 17.9: Bio-Rad Laboratories, Inc.: Overall Financials, 2017-2019
Figure 17.10: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2017-2019
Figure 17.11: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2017-2019
Figure 17.12: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2017-2019
Figure 17.13: SWOT Analysis: Bio-Rad Laboratories Inc.
Figure 17.14: Cynvenio Biosystems: Portfolio
Figure 17.15: SWOT Analysis: Cynvenio Biosystems Inc.
Figure 17.16: Chronix Biomedical: Portfolio
Figure 17.17: SWOT Analysis: Chronix Biomedical
Figure 17.18: Epic Sciences: Portfolio
Figure 17.19: SWOT Analysis: Epic Sciences
Figure 17.20: F. Hoffmann-La Roche Ltd: Portfolio
Figure 17.21: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
Figure 17.22: F. Hoffmann-La Roche Ltd: Sales (by Segment), 2017-2019
Figure 17.23: F. Hoffmann-La Roche Ltd: Sales (by Region), 2017-2019
Figure 17.24: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
Figure 17.25: SWOT Analysis: F. Hoffmann-La Roche Ltd.
Figure 17.26: Guardant Health: Portfolio
Figure 17.27: Guardant Health: Overall Financials, 2017-2019
Figure 17.28: Guardant Health: Sales (by Segment), 2017-2019
Figure 17.29 Guardant Health: Sales (by Region), 2017-2019
Figure 17.30: Guardant Health: R&D Expenditure, 2017-2019
Figure 17.31: SWOT Analysis: Guardant Health Inc.
Figure 17.32: Illumina Inc. Portfolio
Figure 17.33: Illumina, Inc.: Overall Financials, 2017-2019
Figure 17.34: Illumina, Inc.: Revenue (by Segment), 2017-2019
Figure 17.35: Illumina, Inc.: Revenue (by Region), 2017-2019
Figure 17.36: Illumina, Inc.: R&D Expenditure, 2017-2019
Figure 17.37: SWOT Analysis: Illumina Inc.
Figure 17.38: Menarini Silicon Biosystems: Portfolio
Figure 17.39: SWOT Analysis: Menarini Silicon Biosystems
Figure 17.40: Neogenomics Laboratories: Portfolio
Figure 17.41: NeoGenomics Laboratories, Inc.: Overall Financials, 2017-2019
Figure 17.42: NeoGenomics Laboratories, Inc.: Revenue (by Segment), 2017-2019
Figure 17.43: NeoGenomics Laboratories, Inc.: R&D Expenditure, 2017-2019
Figure 17.44: SWOT Analysis: Neogenomics Laboratories
Figure 17.45: Personal Genome Diagnostics: Portfolio
Figure 17.46: SWOT Analysis: Personal Genome Diagnostics
Figure 17.47: QIAGEN N.V.: Portfolio
Figure 17.48: QIAGEN N.V.: Overall Financials, 2017-2019
Figure 17.49: QIAGEN N.V.: Revenue (by Segment), 2017-2019
Figure 17.50: QIAGEN N.V.: Revenue (by Region), 2017-2019
Figure 17.51: QIAGEN N.V.: R&D Expenditure, 2017-2019
Figure 17.52: SWOT Analysis: Qiagen N.V.
Figure 17.53: Resolution Biosciences: Portfolio
Figure 17.53: SWOT Analysis: Resolution Biosciences
Figure 17.54: Thermo Fisher Scientific: Portfolio
Figure 17.55: Thermo Fisher Scientific Inc.: Overall Financials, 2017-2019
Figure 17.56: Thermo Fisher Scientific Inc: Sales (by Segment), $Million, 2017-2019
Figure 17.57: Thermo Fisher Scientific Inc.: Sales (by Region), 2017-2019
Figure 17.58: Thermo Fisher Scientific Inc.: R&D Expenditure, 2017-2019
Figure 17.59: SWOT Analysis: Thermo Fisher Scientific Inc.
Figure 10.41: Exact Sciences: Portfolio
Figure 17.60: Exact Sciences Corporation: Overall Financials, 2017-2019
Figure 17.61: Exact Sciences Corporation: Sales (by Segment), $Million, 2017-2019
Figure 17.62: Exact Sciences Corporation.: Sales (by Region), 2017-2019
Figure 17.63: Exact Sciences Corporation: R&D Expenditure, 2017-2019
Figure 17.64: SWOT Analysis: Exact Sciences Corporation
Figure 17.65: Natera Inc.Product Portfolio.
Figure 17.66: Natera Inc: Overall Financials, 2017-2019
Figure 17.67: Natera Inc.: Sales (by Segment), $Million, 2017-2019
Figure 17.68: Exact Sciences Corporation.: Sales (by Region), 2017-2019
Figure 17.69: Natera Inc.: R&D Expenditure, 2017-2019
Figure 17.70: SWOT Analysis: Natera Inc.
Figure 17.71: GRAIL: Portfolio
Figure 17.72: SWOT Analysis: GRAIL
Figure 17.73: Freenome: Portfolio
Figure 17.74: SWOT Analysis: Freenome
Figure 17.75: Thrive Earlier Detection: Portfolio
Figure 17.76: SWOT Analysis: Thrive Earlier Detection
